Oric Pharmaceuticals (ORIC) Non Operating Income (2019 - 2026)

Oric Pharmaceuticals' Non Operating Income history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Non Operating Income rose 42.83% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (up 6.72% YoY) and the FY2025 annual result came in at $13.5 million, down 10.05% from the prior year.
• Non Operating Income was $3.9 million for Q1 2026 at Oric Pharmaceuticals, down from $4.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.1 million in Q3 2025 and bottomed at $99000.0 in Q1 2022.
• A 5-year average of $2.7 million and a median of $3.1 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 2783.33% — and 2025, when it sank 33.18%.
• Oric Pharmaceuticals' Non Operating Income stood at $1.3 million in 2022, then surged by 143.55% to $3.1 million in 2023, then grew by 5.33% to $3.3 million in 2024, then climbed by 24.0% to $4.0 million in 2025, then slipped by 4.79% to $3.9 million in 2026.
• Business Quant data shows ORIC's Non Operating Income at $3.9 million in Q1 2026, $4.0 million in Q4 2025, and $4.1 million in Q3 2025.